Fig. 3From: Prognostic markers in patients with chronic lymphocytic leukaemia on targeted therapy, chemoimmunotherapy with anti-CD20 monoclonal antibody: a systematic review and meta-analysis of prognostic factorsMeta-analysis of the hazards ratios (HR) for progression-free survival (PFS) for CLL patients treated with Anti-CD20 mAb containing CIT and standard chemotherapy alone or targeted therapyBack to article page